Sinovac Biotech, Ltd (SVA) Posts Q2 Loss of 4c/Share

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q2 EPS of ($0.04), $0.04 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12.1 million versus the consensus estimate of $17.2 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Rexford Industrial agrees to sell $1.2B portfolio to EQT Real Estate
• Palogic urges Granite Point Mortgage to cut costs, halt new loans